Live intraday price
Compare with our price levels
Close 2026-09-30: $86.32 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Near the buy zone — 1.4% above the first entry · 1 whale recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 3.1Moves ~$2.16 a day
⚖️ Positives and risks
- ●1 whale bought or added last quarter
- ●Long-term uptrend (above a rising MA200)
- ●Average analyst price target 100.96 (upside +17%, 26 analysts)
- ●Most analysts rate it Buy
- ●2 whales sold or trimmed: Joel Greenblatt (trimmed), Andreas Halvorsen (sold out)
- ●MACD just crossed down (momentum fading)
- ●Lagged the market (S&P 500) by -10% over 6 months
- ●Earnings down -25% year over year
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
👔 Insider buying & selling
Latest trades from SEC Form 4 filings
Lippis Daniel J. · Officer
2026-09-11 · 619 shares @ $87.51 · pre-planned sale (10b5-1)
Dahl Andrew M. · Officer
2026-08-31 · 544 shares @ $91.06
Bruls Annette · Officer
2026-08-28 · 2,644 shares @ $89.98
Chopra Daveen · Officer
2026-08-26 · 30,646 shares @ $90.99
Markowitz Wayne · Officer
2026-08-26 · 1,240 shares @ $91.47
Chopra Daveen · Officer
2026-08-26 · 1,154 shares @ $91.76
Lippis Daniel J. · Officer
2026-08-11 · 619 shares @ $92.03 · pre-planned sale (10b5-1)
Markowitz Wayne · Officer
2026-07-30 · 146 shares @ $86.03
Markowitz Wayne · Officer
2026-07-28 · 9,628 shares @ $85.06
Zovighian Bernard J · CEO · Director
2026-07-27 · 2,921 shares @ $83.93
Lippis Daniel J. · Officer
2026-07-10 · 619 shares @ $91.70 · pre-planned sale (10b5-1)
Lippis Daniel J. · Officer
2026-06-30 · 619 shares @ $91.40 · pre-planned sale (10b5-1)
Zovighian Bernard J · CEO · Director
2026-06-17 · 523 shares @ $87.92 · pre-planned sale (10b5-1)
Dahl Andrew M. · Officer
2026-05-29 · 568 shares @ $86.08
BOBO DONALD E JR · Officer
2026-05-27 · 23,145 shares @ $86.42
📊 Past earnings and price reaction
Actual EPS vs. analyst estimates · the price move on the first trading day after the report and over the next 20 trading days
Actual EPS $0.78 · est. $0.74 · After close
Day 1
Next 20 days
Actual EPS $0.78 · est. $0.73 · After close
Day 1
Next 20 days
Actual EPS $0.58 · est. $0.62 · After close
Day 1
Next 20 days
Actual EPS $0.67 · est. $0.59 · After close
Day 1
Next 20 days
Actual EPS $0.67 · est. $0.62 · After close
Day 1
Next 20 days
Actual EPS $0.64 · est. $0.60 · After close
Day 1
Next 20 days
Actual EPS $0.59 · est. $0.55 · After close
Day 1
Next 20 days
Actual EPS $0.67 · est. $0.59 · After close
Day 1
Next 20 days
Listen to the earnings call or read the full report on EW's investor relations page ↗ · Earnings data from Yahoo Finance
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
Simply Wall St. · 2026-09-18
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion
Simply Wall St. · 2026-09-18
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
MarketBeat · 2026-09-17
CMS expands TAVR Medicare coverage to asymptomatic patients
MedTech Dive · 2026-09-11
Is Edwards Lifesciences Stock Underperforming the Dow?
Barchart · 2026-09-08
🔬 Deep dive
For those who want the detailed numbers